High-calcium vs high-phosphate intake and small artery tone in advanced experimental renal insufficiency

Nephrology Dialysis Transplantation

Volumn 21, Issue 10, 2006, Pages 2754-2761

  Kööbi, Peeter ^a,b   Vehmas, Tuija I ^a   Jolma, Pasi ^a,c   Kalliovalkama, Jarkko ^a,d   Fan, Meng ^a   Niemelä, Onni ^e   Saha, Heikki ^a,c   Kähönen, Mika ^c   Ylitalo, Pauli ^a   Rysä, Jaana ^f   Ruskoaho, Heikki ^f   Pörsti, Ilkka ^a,c  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b SATAKUNTA CENTRAL HOSPITAL   (Finland)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d Coxa Hospital for Joint Replacement ^*  (Finland)

^e SEINÄJOKI CENTRAL HOSPITAL   (Finland)

^f UNIVERSITY OF OULU   (Finland)

Author keywords

Arterial function; Calcium; Endothelium; Kidney failure chronic; Phosphate; PTH

Indexed keywords

ACETYLCHOLINE; BRAIN NATRIURETIC PEPTIDE; CALCIUM; CREATININE; NITRIC OXIDE; PARATHYROID HORMONE; PHOSPHATE; POTASSIUM CHANNEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY TONE; ARTICLE; BLOOD PRESSURE; CALCIUM INTAKE; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE COURSE; KIDNEY FAILURE; MALE; MESENTERIC ARTERY; NEPHRECTOMY; NONHUMAN; PEPTIDE SYNTHESIS; PHOSPHATE INTAKE; PRIORITY JOURNAL; RAT; SECONDARY HYPERPARATHYROIDISM; UREMIA; VASODILATATION;

8,11,14-EICOSATRIENOIC ACID; ACETYLCHOLINE; ANIMALS; ARTERIES; BLOOD PRESSURE; CALCIUM; CALCIUM, DIETARY; CREATINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM; HYPERPARATHYROIDISM; MALE; MESENTERIC ARTERIES; NITROPRUSSIDE; PARATHYROID HORMONE; PHOSPHATES; PHOSPHORUS, DIETARY; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RENAL INSUFFICIENCY; TIME FACTORS; VASODILATION;

EID: 33749640315     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl270     Document Type: Article

References (20)

1. Tyralla K, Amann K. Morphology of the heart and arteries in renal failure. Kidney Int 2003; 63 [Suppl 84): S80-S83
2. Safar ME, London GM, Plante GE. Arterial stiffness and kidney function. Hypertension 2004; 43: 163-168
3. Morris ST, McMurray JJ, Spiers A, Jardine AG. Impaired endothelial function in isolated human uremic resistance arteries. Kidney Int 2001; 60: 1077-1082
4. Jolma P, Kööbi P, Kalliovalkama J et al. Treatment of secondary hyperparathyroidism by high calcium diet is associated with enhanced resistance artery relaxation in experimental renal failure. Nephrol Dial Transplant 2003; 18: 2560-2569
5. Rostand SG, Drüeke TB. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 1999; 56: 383-392
6. Marco MP, Craver L, Betriu A, Belart M, Fibla J, Fernandez E. Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population. Kidney Int Suppl 2003; 63 [Suppl 85]: S111-S114
7. Amann K, Tyralla K, Gross ML, Eifert T, Adamczak M, Ritz E. Special characteristics of atherosclerosis in chronic renal failure. Clin Nephrol 2003; 60 [Suppl 1]: S13-S21
8. Nilsson IL, Aberg J, Rastad J, Lind L. Endothelial vasodilatory dysfunction in primary hyperparathyroidism is reversed after parathyroidectomy. Surgery 1999; 126: 1049-1055
9. Chertow GM, Raggi P, Chasan-Taber S, Bommer J, Holzer H, Burke SK. Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 1489-1496
10. Pörsti I, Fan M, Kööbi P et al. High calcium diet down-regulates kidney angiotensin-converting enzyme in experimental renal failure. Kidney Int 2004; 66: 2155-2166
11. Kööbi P, Kalliovalkama J, Jolma P et al. AT1 receptor blockade improves vasorelaxation in experimental renal failure. Hypertension 2003; 41: 1364-1371
12. Magga J, Marttila M, Mäntymaa P, Vuolteenaho O, Ruskoaho H. Brain natriuretic peptide in plasma, atria, and ventricles of vasopressin- and phenylephrine-infused conscious rats. Endocrinology 1994; 134: 2505-2515
13. Mulvany MJ. Vascular remodelling of resistance vessels, can we define this? Cardiovasc Res 1999; 41: 9-13
14. Hatton DC, McCarron DA. Dietary calcium and blood pressure in experimental models of hypertension. A review. Hypertension 1994; 23: 513-530
15. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 2002; 82: 131-185
16. Fliser D, Kielstein JT, Haller H, Bode-Boger SM. Asymmetric dimethylarginine: A cardiovascular risk factor in renal disease? Kidney Int Suppl 2003; 63 [Suppl 84]: S37-S40
17. Xiao S, Erdely A, Wagner L, Baylis C. Uremic levels of BUN do not cause nitric oxide deficiency in rats with normal renal function. Am J Physiol Renal Physiol 2001; 280: F996-F1000
18. Vaziri ND, Ni Z, Wang XQ, Oveisi F, Zhou XJ. Downre0gulation of nitric oxide synthase in chronic renal insufficiency: Role of excess PTH. Am J Physiol 1998; 274: F642-F649
19. Slatopolsky E, Brown A, Dusso A. Role of phosphorus in the pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 2001; 37: S54-S57
20. Farzaneh-Far A, Proudfoot D, Weissberg PL, Shanahan CM. Matrix gla protein is regulated by a mechanism functionally related to the calcium-sensing receptor. Biochem Biophys Res Commun 2000; 277: 736-740